Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + apatinib + platinum chemotherapy as neoadjuvant therapy for potentially resectable thymic carcinoma (Phase II)
ChiCTR2600121533Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and Rivoceranib in thymic carcinoma (TC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathological complete response. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2600121533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121533.